| 词条 | Gantenerumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458275293 | image = | type = mab | mab_type = mab | source = u | target = Beta-amyloid (Aβ40/42) | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|CAS}} | CAS_number = 1043556-46-2 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 4DF060P933 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D09680 | C=6496 | H=10072 | N=1740 | O=2024 | S=42 | molecular_weight = 146.3 kg/mol (peptide) }}Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3] Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.[4] One clinical study was stopped on December 19, 2014 after disappointing results.[5] As of late 2014, Phase III clinical trials are ongoing.[6] References1. ^Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association. {{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{monoclonal-antibody-stub}}{{nervous-system-drug-stub}}2. ^International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization. 3. ^{{ClinicalTrialsGov|NCT00531804|A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease}} 4. ^http://www.scarletroadstudy.com/en-CA/index.aspx 5. ^http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045 6. ^{{cite journal| author = H. Spreitzer| date = 10 November 2014| title = Neue Wirkstoffe – Gantenerumab| journal = Österreichische Apothekerzeitung| issue = 23/2014| page = 55| language = German}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。